Literature DB >> 17762961

5-Lipoxygenase is coexpressed with Cox-2 in sporadic colorectal cancer: a correlation with advanced stage.

Valeria Barresi1, Maddalena Grosso, Enrica Vitarelli, Giovanni Tuccari, Gaetano Barresi.   

Abstract

PURPOSE: It has been extensively documented that the cyclooxygenase inducible form and 15-lipoxygenase are implicated in colorectal carcinogenesis. Nonetheless, the role of other enzymes involved in the arachidonic acid metabolism, such as 5-lipoxygenase, in colorectal neoplasms has not been fully ascertained. This study was designed to evaluate 5-lipoxygenase expression in sporadic colorectal adenocarcinomas by using immunohistochemistry and to analyze its potential correlations with clinicopathologic parameters and with cyclooxygenase-2 expression.
METHODS: Expression of 5-lipoxygenase and cyclooxygenase-2 were evaluated by immunohistochemistry in 50 surgically resected sporadic colorectal adenocarcinomas (28 male and 22 female patients age range, 47-88 (mean age, 69 +/- 8) years). The chi-squared and Spearman correlation tests were used to analyze correlations with clinicopathologic characteristics and to evaluate any relationships between expression of the two enzymes. P values <0.05 were considered statistically significant.
RESULTS: 5-Lipooxygenase and cyclooxygenase-2 immunostaining was found in the cytoplasm of neoplastic cells in 41 (82 percent) and in 43 cases (86 percent), respectively. Spearman correlation test demonstrated a positive correlation in the expression of the two enzymes. A statistically significant correlation also was observed between 5-lipoxygenase expression and tumor stage and lymph node metastasis, whereas no significant correlations emerged regarding cyclooxygenase-2 expression and clinicopathologic parameters.
CONCLUSIONS: Our study demonstrates that 5-lipoxygenase is expressed in colorectal adenocarcinomas in association with cyclooxygenase-2 expression. Moreover, an elevated expression of this enzyme seems to be significantly correlated with tumor aggressiveness. Further studies would clarify the need for target therapies inhibiting both metabolic pathways in such tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762961     DOI: 10.1007/s10350-007-0311-9

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  5 in total

1.  Knock-out of 5-lipoxygenase in overexpressing tumor cells-consequences on gene expression and cellular function.

Authors:  Hannah Weisser; Tamara Göbel; G Melissa Krishnathas; Marius Kreiß; Carlo Angioni; Duran Sürün; Dominique Thomas; Tobias Schmid; Ann-Kathrin Häfner; Astrid S Kahnt
Journal:  Cancer Gene Ther       Date:  2022-09-16       Impact factor: 5.854

2.  MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.

Authors:  Richard E Kast; Alex Alfieri; Hazem I Assi; Terry C Burns; Ashraf M Elyamany; Maria Gonzalez-Cao; Georg Karpel-Massler; Christine Marosi; Michael E Salacz; Iacopo Sardi; Pieter Van Vlierberghe; Mohamed S Zaghloul; Marc-Eric Halatsch
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

3.  11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis.

Authors:  Shilin Yang; Li Jiang; Ming-Zhi Zhang
Journal:  J Oncobiomarkers       Date:  2013

4.  12/15 Lipoxygenase regulation of colorectal tumorigenesis is determined by the relative tumor levels of its metabolite 12-HETE and 13-HODE in animal models.

Authors:  Jian Chang; Li Jiang; Yinqiu Wang; Bing Yao; Shilin Yang; Bixiang Zhang; Ming-Zhi Zhang
Journal:  Oncotarget       Date:  2015-02-20

Review 5.  Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway.

Authors:  Gillian Y Moore; Graham P Pidgeon
Journal:  Int J Mol Sci       Date:  2017-01-24       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.